InvestorsHub Logo
Followers 27
Posts 1204
Boards Moderated 0
Alias Born 09/11/2010

Re: bra1loga post# 63290

Friday, 01/11/2013 1:19:12 PM

Friday, January 11, 2013 1:19:12 PM

Post# of 97237
TTNP current valuation is extremely cheap especially if peak sales of their drug hits Analysts Est of 300 to 500 million dollars also adding in upon approval TTNP will have over 80 million dollars in Cash...Currently 125 Million dollar market cap ??? $2's look like a lock real soon imo...

Jan 7th Investor Presentation Note Nasdaq Up listing for early 2013

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001193125%2D13%2D004375%2Etxt&FilePath=%5C2013%5C01%5C07%5C&CoName=TITAN+PHARMACEUTICALS+INC&FormType=8%2DK&RcvdDate=1%2F7%2F2013&pdf=

Analyst Jason Napodano, CFA

http://bionapcfa.blogspot.com/search/label/Titan%20Pharma

priority review press release

http://finance.yahoo.com/news/probuphine-r-receives-fda-priority-120000404.html

Titan's partner deal press release note the 75 Million dollars pledged by partner for commercial roll out of Probuphine.

http://finance.yahoo.com/news/titan-pharmaceuticals-licenses-exclusive-probuphine-120000246.html

Pre partner analyst article naming TTNP & reasons for buying with $4.00 target.

http://seekingalpha.com/article/1064451-do-you-have-the-guts-to-take-on-cutting-edge-biotech-like-this-vc?source=yahoo

A Wall street journal article on opioid addiction & Titans treatment option

http://online.wsj.com/article/SB10001424052702303684004577506983158087406.html?KEYWORDS=titan#articleTabs%3Darticle

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.